Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabry disease
Biotech
Sangamo slashes time to market for Fabry gene therapy
Sangamo aligned with the FDA on a pathway that could slash three years from the time to market and free it from the need to run an additional study.
Nick Paul Taylor
Oct 22, 2024 12:57pm
Relay loses interest in SHP2 inhibitor after Genentech leaves
Aug 7, 2024 6:00am
Crosswalk grabs compounds from abandoned Takeda, Codexis collab
Jul 2, 2024 9:55am
Sangamo lays off 27% of US staff in latest refocus
Apr 27, 2023 8:55am
FDA slaps hold on 4DMT's phase 1/2 gene therapy trial
Feb 3, 2023 1:28pm
4D's Fabry gene therapy flounders amid adverse events
Jan 11, 2023 10:15am
